Uncategorized Archives - Page 31 of 142

MondayAug 14, 2023 11:15 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics

Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030 The monoclonal antibodies market was valued at $210.06 billion in 2022, and it is expected to reach $494.53 billion by 2030 The nanobody market was valued $237.1 million in 2021 and is expected reach a value of $1.07 billion by 2028 BiondVax is uniquely positioned to rapidly advance from R&D towards commercialization BiondVax Pharmaceuticals (NASDAQ: BVXV), a…

MondayAug 14, 2023 9:00 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

In June 2023, Renovaro announced that a potential IND application for its innovative cancer platform is on track for early 2024 FDA submission The company in March 2023 announced proof-of-concept for its proprietary technology to treat pancreatic tumors In August 2023, Renovaro announced its entry into a Letter of Intent to merge with GEDi Cube International Ltd. with the aim of accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases As of August 2023, Renovaro has raised total cash of $82.7 million The company’s IP portfolio covering gene and gene-modified…

FridayJul 28, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent

Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda The company has received patent protection for the REQORSA-Keytruda drug combination in the U.S., Japan, Australia, Russia, Mexico, and China, meaning the company has secured exclusivity in many of the largest markets The granted patents, three Fast Track Designations, and positive preclinical…

WednesdayJul 26, 2023 9:45 am

M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion as evidence of the potential value of BiondVax in this segment of the therapeutics market DICE Therapeutics is currently evaluating its lead drug candidate, DC-806, an oral IL-17 inhibitor, in a Phase II trial, with early-stage results from the Phase I study showing a near-44% reduction in Psoriasis Area and Severity Index The…

FridayJul 21, 2023 9:00 am

National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal clinical trial for its lead pharmaceutical candidate, Berubicin, which it aims to show improves on standard of care chemotherapy agent Lomustine’s approach to treating GBM Berubicin is a novel anthracycline that is practically unique in its ability to cross the blood-brain barrier to directly target…

WednesdayJul 19, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast

Reichman discusses BiondVax’s 2023 achievements, including the development of innovative NanoAbs in collaboration with the Max Planck Institute targeting interleukin-17 (IL-17) targeting diseases such as psoriasis Annual sales for current anti-interleukin-17 monoclonal antibodies now total about $7.5 billion annually – and BiondVax is positioned to penetrate this market with promising results Investor Brand Network (“IBN”) recently announced the release of its latest episode of The Bell2Bell Podcast, featuring Amir Reichman, CEO of BiondVax Pharmaceuticals (NASDAQ: BVXV). The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries – like BiondVax’s innovative platform technology using alpaca-derived nanosized…

WednesdayJul 12, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Sees Hot Market Potential for NanoAb Pipeline

The global dermatology pharmaceutics market is booming, with increased public awareness and large unmet needs BiondVax competitor MoonLake Immunotherapeutics share price jumped 128% after positive findings from a Phase 2 trial evaluating Nanobody(R) sonelokimab in patients with moderate-to-severe hidradenitis suppurativa, a painful long-term dermatological condition BiondVax’s NanoAbs address psoriasis and a broad range of other diseases, and with a potentially better safety profile based on administration directly into lesions, rather than MoonLake’s systemic-administration The global dermatology pharmaceutics market was valued just over $20 billion in 2022 and is expected to surge to nearly $40 billion by 2030, growing at a…

MondayJul 10, 2023 9:00 am

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients…

ThursdayJul 06, 2023 9:00 am

Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3

Genprex recently received a Fast Track Designation (“FTD”) from the FDA for its REQORSA(R) Immunogene Therapy in combination with Genentech, Inc.’s Tecentriq(R) in patients with extensive-stage small cell lung cancer This is Genprex’s third FTD and sets the stage for the initiation of its third lung cancer clinical trial, Acclaim-3 Acclaim-3 clinical trial is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq The company expects to enroll the first patient in its Acclaim-3 clinical trial in the third quarter of 2023 Genprex is combining its lead product candidate, REQORSA, with…

MondayJul 03, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Offering to Include Boutique End-to-End CDMO Services

BiondVax’s CDMO services allow the company to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services BiondVax showcased its boutique end-to-end CDMO offering at the annual Biomed Conference in Tel Aviv in May BiondVax’s cGMP biologics manufacturing facility in Jerusalem is fully equipped with state-of-the-art CDMO capabilities The expansion of CDMO services will augment revenue and expand pharma contacts while still maintaining BiondVax’s core focus of NanoAb therapies for significant indications like COVID-19, psoriasis, asthma, and more BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics

Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent

M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Sees Hot Market Potential for NanoAb Pipeline

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Offering to Include Boutique End-to-End CDMO Services

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search